The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ...
Air route diversions and constrained regional access are eroding schedule certainty for temperature-controlled air freight, ...
U.S. District Judge David Joseph, a Trump appointee sitting in Lafayette, Louisiana, refused Louisiana Attorney General Liz ...
In these gray areas, an advisory committee can be essential; it allows for a real-time debate on the benefit-risk profile ...
Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...
Companion diagnostics (CDx), positioned at the intersection of pathology, drug development, and patient access, have emerged ...
The most immediate impacts of the U.S.- Iran conflict is being observed in the supply of active pharmaceutical ingredients ...
GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, ...
Copay misuse at the pharmacy isn't always intentional, but the cost to your program is the same either way. Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results